{"title":"Biomarkers in muscle invasive bladder cancer.","authors":"Fiona Wilson, Nuradh Joseph, Ananya Choudhury","doi":"10.1016/bs.acc.2021.07.005","DOIUrl":null,"url":null,"abstract":"<p><p>Muscle invasive bladder cancer (MIBC) carries a poor prognosis with a 5-year overall survival rate of 40-50%. For localized disease, radical treatment options are cystectomy or radiotherapy with or without a radiosensitiser. Neoadjuvant or adjuvant chemotherapy is often delivered in addition to either. Metastatic disease can be treated with palliative systemic chemotherapy or immunotherapy. Standard clinicopathological information is insufficient to guide treatment decisions in several clinical scenarios in MIBC and there has been substantial effort to identify predictive and prognostic biomarkers. Despite this, no biomarker has been sufficiently qualified in prospective clinical trials to justify routine use. In this chapter we discuss these biomarkers and provide insight into the significant unmet need for robust biomarkers to inform treatment decisions and ultimately improve outcomes for bladder cancer patients.</p>","PeriodicalId":50872,"journal":{"name":"Advances in Clinical Chemistry","volume":" ","pages":"265-297"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acc.2021.07.005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Chemistry","Score":null,"Total":0}
引用次数: 4
Abstract
Muscle invasive bladder cancer (MIBC) carries a poor prognosis with a 5-year overall survival rate of 40-50%. For localized disease, radical treatment options are cystectomy or radiotherapy with or without a radiosensitiser. Neoadjuvant or adjuvant chemotherapy is often delivered in addition to either. Metastatic disease can be treated with palliative systemic chemotherapy or immunotherapy. Standard clinicopathological information is insufficient to guide treatment decisions in several clinical scenarios in MIBC and there has been substantial effort to identify predictive and prognostic biomarkers. Despite this, no biomarker has been sufficiently qualified in prospective clinical trials to justify routine use. In this chapter we discuss these biomarkers and provide insight into the significant unmet need for robust biomarkers to inform treatment decisions and ultimately improve outcomes for bladder cancer patients.
期刊介绍：
Advances in Clinical Chemistry volumes contain material by leading experts in academia and clinical laboratory science. The reviews cover a wide variety of clinical chemistry disciplines including clinical biomarker exploration, cutting edge microarray technology, proteomics and genomics. It is an indispensable resource and practical guide for practitioners of clinical chemistry, molecular diagnostics, pathology, and clinical laboratory sciences in general.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
